{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:22:45Z","timestamp":1789521765668,"version":"build-2803163510"},"reference-count":101,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.dld.2023.08.062","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T12:38:29Z","timestamp":1695645509000},"page":"579-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-942X","authenticated-orcid":false,"given":"Elisa","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Meneghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Farinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Pelizzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Gambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2023.08.062_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.dld.2023.08.062_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010500","article-title":"Hepatocellular carcinoma in chronic viral hepatitis: where do we stand?","volume":"23","author":"Russo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.dld.2023.08.062_bib0004","article-title":"Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002\u20132033: the ITA.LI.CA database","author":"Vitale","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.062_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040897","article-title":"Surveillance as determinant of long-term survival in non-transplanted hepatocellular carcinoma patients","volume":"13","author":"Pelizzaro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2023.08.062_bib0006","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.062_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.08.062_bib0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.08.062_bib0010","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.062_bib0011","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0012","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2023.08.062_bib0014","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.dld.2023.08.062_bib0016","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.3390\/cancers14194616","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"14","author":"De Lorenzo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2023.08.062_bib0017","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0018","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.dld.2023.08.062_bib0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.dld.2023.08.062_bib0021","first-page":"006","article-title":"PD-L1\/PD-1 co-stimulation, a brake for T cell activation and a t cell differentiation signal","volume":"S12","author":"Liechtenstein","year":"2012","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.dld.2023.08.062_bib0022","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.08.062_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0024","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0026","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1200\/JCO.2022.40.16_suppl.4088","article-title":"Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study","volume":"40","author":"Qin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0027","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/cancers12051089","article-title":"Scientific rationale for combined immunotherapy with PD-1\/PD-L1 antibodies and vegf inhibitors in advanced hepatocellular carcinoma","volume":"12","author":"Kudo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2023.08.062_bib0028","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.dld.2023.08.062_bib0029","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0032","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000486487","article-title":"Combination cancer immunotherapy in hepatocellular carcinoma","volume":"7","author":"Kudo","year":"2018","journal-title":"Liver Cancer"},{"key":"10.1016\/j.dld.2023.08.062_bib0033","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0034","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.031","article-title":"LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus len-vatinib as first-line (1 L) therapy for advanced hepatocellular carcinoma (aHCC)","volume":"33","author":"Finn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0035","article-title":"LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"BA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2023.08.062_bib0037","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0038","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal analysis of early immune responses in patients with acute hepatitis B virus infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2023.08.062_bib0039","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","article-title":"Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma","volume":"68","author":"Lim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.062_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and adaptive immune responses in HCV infections","volume":"61","author":"Heim","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0041","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2019.08.014","article-title":"The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications","volume":"72","author":"Hou","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0042","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/hep.20454","article-title":"An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection","volume":"40","author":"Cabrera","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0043","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2026184118","article-title":"Hepatitis C virus modulates signal peptide peptidase to alter host protein processing","volume":"118","author":"Hirano","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.dld.2023.08.062_bib0044","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/gut.46.2.260","article-title":"Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection","volume":"46","author":"McGuinness","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.062_bib0045","doi-asserted-by":"crossref","first-page":"e1004032","DOI":"10.1371\/journal.ppat.1004032","article-title":"Hepatitis B virus infection and immunopathogenesis in a humanized mouse model: induction of human-specific liver fibrosis and M2-like macrophages","volume":"10","author":"Bility","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.dld.2023.08.062_bib0046","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","article-title":"Role of Kupffer cells in the pathogenesis of liver disease","volume":"12","author":"Kolios","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2023.08.062_bib0047","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.dld.2011.11.005","article-title":"Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-\u03b21 over pro-inflammatory cytokines","volume":"44","author":"Li","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2023.08.062_bib0048","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.29170","article-title":"Hepatitis C virus\u2013induced CCL5 secretion from macrophages activates hepatic stellate cells","volume":"66","author":"Sasaki","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0049","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nri.2017.11","article-title":"Liver macrophages in tissue homeostasis and disease","volume":"17","author":"Krenkel","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.dld.2023.08.062_bib0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0051","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/gutjnl-2020-321702","article-title":"Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups","volume":"70","author":"Pinter","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.062_bib0052","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0053","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0054","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0055","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature16969","article-title":"NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis","volume":"531","author":"Ma","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0056","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10599","article-title":"Senescence surveillance of pre-malignant hepatocytes limits liver cancer development","volume":"479","author":"Kang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.dld.2023.08.062_bib0057","first-page":"496","article-title":"M2 activation and obesity","volume":"7","author":"Odegaard","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.dld.2023.08.062_bib0058","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1053\/j.gastro.2015.12.037","article-title":"Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes","volume":"150","author":"Hirsova","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.08.062_bib0059","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s00248-010-9801-8","article-title":"Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection","volume":"61","author":"Lu","year":"2011","journal-title":"Microb Ecol"},{"key":"10.1016\/j.dld.2023.08.062_bib0060","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10620-009-0870-9","article-title":"Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients","volume":"55","author":"Jun","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2023.08.062_bib0061","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.3389\/fmicb.2017.02222","article-title":"Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients","volume":"88","author":"Wang","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.dld.2023.08.062_bib0062","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1007\/s10096-015-2464-0","article-title":"Gut microbiota modulate the immune effect against hepatitis B virus infection","volume":"34","author":"Xu","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.dld.2023.08.062_bib0063","first-page":"55","article-title":"Changes of gut-microbiota-liver axis in hepatitis C virus infection","volume":"10","author":"El-Mowafy","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.dld.2023.08.062_bib0064","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/cid\/ciy205","article-title":"Gut dysbiosis associated with hepatitis C virus infection","volume":"67","author":"Inoue","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.dld.2023.08.062_bib0065","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17474124.2017.1343663","article-title":"Gut microbiota changes and chronic hepatitis C virus infection","volume":"11","author":"Preveden","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0066","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/microorganisms7050121","article-title":"Role of gut microbiota in hepatocarcinogenesis","volume":"7","author":"Gupta","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.dld.2023.08.062_bib0067","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13099-016-0124-2","article-title":"Gut microbiome alterations in patients with stage 4 hepatitis C","volume":"8","author":"Aly","year":"2016","journal-title":"Gut Pathog"},{"key":"10.1016\/j.dld.2023.08.062_bib0068","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.31700","article-title":"Eradication of chronic HCV Infection: improvement of dysbiosis only in patients without liver cirrhosis","volume":"74","author":"Wellh\u00f6ner","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0069","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/apt.15004","article-title":"Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis","volume":"48","author":"Ponziani","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.08.062_bib0070","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/apt.13732","article-title":"HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients","volume":"44","author":"Bajaj","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2023.08.062_bib0071","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/ph14090931","article-title":"Pilot sub-study of the effect of hepatitis c cure by glecaprevir\/pibrentasvir on the gut microbiome of patients with chronic hepatitis c genotypes 1 to 6 in the mythen study","volume":"14","author":"Yilmaz","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.dld.2023.08.062_bib0072","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hep.26093","article-title":"Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH","volume":"57","author":"Zhu","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0073","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/hep.28356","article-title":"The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota","volume":"63","author":"Boursier","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/femsec\/fiu002","article-title":"Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease","volume":"91","author":"Michail","year":"2015","journal-title":"FEMS Microbiol Ecol"},{"key":"10.1016\/j.dld.2023.08.062_bib0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.dld.2023.08.062_bib0076","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2105\/AJPH.2010.300106","article-title":"Effectiveness of a community health worker intervention among African American and Latino adults with type 2 diabetes: a randomized controlled trial","volume":"101","author":"Spencer","year":"2011","journal-title":"Am J Public Health"},{"key":"10.1016\/j.dld.2023.08.062_bib0077","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/MEG.0000000000000348","article-title":"Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease","volume":"27","author":"Gangarapu","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0078","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2023.08.062_bib0079","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.3748\/wjg.v27.i42.7340","article-title":"Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients","volume":"27","author":"Chung","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2023.08.062_bib0080","doi-asserted-by":"crossref","first-page":"e003334","DOI":"10.1136\/jitc-2021-003334","article-title":"Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers","volume":"9","author":"Mao","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.dld.2023.08.062_bib0081","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep4.1905","article-title":"Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma","volume":"6","author":"Ponziani","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2023.08.062_bib0082","doi-asserted-by":"crossref","first-page":"e202895","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.dld.2023.08.062_bib0083","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-Based Management of Hepatocellular Carcinoma: systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020)","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2023.08.062_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2023.08.062_bib0085","first-page":"S323","article-title":"714P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)","volume":"33","author":"Chan","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.dld.2023.08.062_bib0086","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.gastro.2023.02.042","article-title":"Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of IMbrave150","volume":"165","author":"Espinoza","year":"2023","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2023.08.062_bib0087","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","article-title":"Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease","volume":"79","author":"Meyer","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2023.08.062_bib0088","first-page":"546","article-title":"Immunotherapy in hepatocellular carcinoma: how does underlying liver disease influence therapeutic strategy and outcomes?","volume":"43","author":"Roth","year":"2022","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.dld.2023.08.062_bib0089","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000389","article-title":"Association between Body Mass Index and Survival Outcomes in Patients Treated with Immune Checkpoint Inhibitors: meta-analyses of Individual Patient Data","volume":"44","author":"Nie","year":"2021","journal-title":"J Immunother"},{"key":"10.1016\/j.dld.2023.08.062_bib0090","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2023.08.062_bib0091","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2023.08.062_bib0092","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2009.188946","article-title":"Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer","volume":"59","author":"Guiu","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.dld.2023.08.062_bib0093","doi-asserted-by":"crossref","first-page":"eaag0945","DOI":"10.1126\/scitranslmed.aag0945","article-title":"Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2","volume":"10","author":"Incio","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dld.2023.08.062_bib0094","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2014.01.031","article-title":"Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer","volume":"133","author":"Slaughter","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0095","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00125-003-1221-6","article-title":"Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects","volume":"46","author":"Miyazawa-Hoshimoto","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.dld.2023.08.062_bib0096","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2023.08.062_bib0097","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.3390\/cancers14194631","article-title":"Non-invasive biomarkers for immunotherapy in patients with hepatocellular carcinoma: current knowledge and future perspectives","volume":"14","author":"Pallozzi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.dld.2023.08.062_bib0098","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/biomedicines11041020","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: current strategies and biomarkers predicting response and\/or resistance","volume":"11","author":"Pelizzaro","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.dld.2023.08.062_bib0099","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2217\/fon-2019-0097","article-title":"RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"15","author":"Qin","year":"2019","journal-title":"Futur Oncol"},{"key":"10.1016\/j.dld.2023.08.062_bib0100","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.dld.2023.08.062_bib0101","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE- 208): a multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2022","journal-title":"Liver Cancer"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865823009404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T12:12:12Z","timestamp":1711195932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865823009404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1590865823009404"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2023.08.062","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2023.08.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}